Icure Pharm Overview

  • Founded
  • 2000
  • Status
  • Public
  • Employees
  • 239
  • Stock Symbol
  • 175250
Stock Symbol
  • Share Price
  • $37.36
  • (As of Thursday Closing)

Icure Pharm General Information


Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • 10 Bongeunsa-Ro 104-Gil, Gangnam-Gu
  • Seoul, Seocho-gu 06170
  • South Korea
+82 00-0000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Icure Pharm Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$37.36 $38.39 $12.14 - $52.86 $272M 7.27M 531K -$1.99

Icure Pharm Financials Summary

In Thousands,
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 280,104 240,866 151,951
Revenue 72,675 52,246 30,316 35,095
EBITDA (4,562) (3,088) (6,171) 1,008
Net Income (12,664) (7,504) (7,174) 474
Total Assets 174,602 186,293 108,201 50,440
Total Debt 56,760 72,832 18,769 20,442
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Icure Pharm Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Icure Pharm‘s full profile, request access.

Request a free trial

Icure Pharm Executive Team (2)

Name Title Board Seat Contact Info
YoungKweon Choi Ph.D Founder & Chief Executive Officer
To view Icure Pharm’s complete executive team members history, request access »

Icure Pharm Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial